Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 20

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 20
---
 receptor antagonist, selectively binding to the PCP-site with an IC50 of approximately 100 µM. Its primary metabolite, Nor-Ketamir, also binds to the PCP-site and does not exhibit affinity for NMDA site, with an IC50 of approximately 300 µM. This targeted receptor interaction differentiates Ketamir-2 from ketamine, which exhibits broader receptor binding, including opioid and monoaminergic receptors, and binds to NMDA receptors with significantly higher affinity (0.5–1 µM). SKNY Pharmaceuticals, Inc. 3014 West Palmira Ave., Suite 302 Tampa, FL 33629 (504) 931-6427 Overview SKNY Pharmaceuticals, Inc. (“SKNY”) is a preclinical-stage pharmaceutical development company focused on next-generation oral therapeutics targeting cannabinoid and dopamine-related pathways. Its lead candidate, SKNY-1, is being developed as a novel oral treatment designed to modulate cannabinoid receptors CB1 and CB2, as well as monoamine oxidase B (MAO-B)—an enzyme involved in dopamine metabolism and addiction regulation. This dual mechanism offers potential applications in both metabolic and addiction-related disorders. If successful, SKNY-1 could address the growing demand for safe and effective therapeutic solutions in areas such as weight management and smoking cessation. In particular:

| ● | SKNY-1,                                                                                                                                
 in preclinical development, is being investigated as a next-generation oral therapeutic targeting metabolic regulation through CB1/CB2 
 receptor modulation and MAO-B inhibition, which play key roles in appetite, metabolism, and energy balance.                            |
| ● | SKNY-1                                                                                                                                 
 is also being evaluated as a potential oral therapy for smoking cessation by modulating cannabinoid signaling and dopamine metabolism, 
 which are both implicated in nicotine dependence and addictive behaviors.                                                              |
| ● | SKNY                                                                                                                                   
 is a licensee of SKNY-1 under a license granted by MIRALOGIX LLC, a Florida limited liability company. The license grants SKNY an      
 exclusive right to make, use and sell SKNY-1 in the United States, Canada and Mexico. The full text of the SKNY-1 Licensing Agreement  
 is attached as Annex E to this proxy statement.                                                                                        |

The Merger (see page 24) The Agreement and Plan of Merger, dated June 16, 2025 (“Merger Agreement”), was entered into by and among MIRA Pharmaceuticals, Inc., a Florida corporation, MIRAPHARM Acquisition